Raymond E. Cabillot Sells 1,100 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,100 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $45.01, for a total transaction of $49,511.00. Following the completion of the sale, the director now owns 318,652 shares in the company, valued at $14,342,526.52. This represents a 0.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Pro-Dex Stock Down 2.7 %

Shares of NASDAQ PDEX opened at $34.34 on Wednesday. The firm’s 50-day simple moving average is $47.15 and its 200 day simple moving average is $34.86. The company has a market cap of $111.95 million, a price-to-earnings ratio of 17.08 and a beta of 0.53. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. Pro-Dex, Inc. has a 12-month low of $16.18 and a 12-month high of $59.60.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, research analysts expect that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PDEX shares. StockNews.com downgraded shares of Pro-Dex from a “strong-buy” rating to a “buy” rating in a research note on Monday. Ascendiant Capital Markets upped their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

Institutional Trading of Pro-Dex

Several institutional investors and hedge funds have recently added to or reduced their stakes in PDEX. Dimensional Fund Advisors LP raised its holdings in Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after purchasing an additional 3,067 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares during the last quarter. Bard Associates Inc. raised its holdings in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after purchasing an additional 2,031 shares during the last quarter. FMR LLC raised its holdings in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the last quarter. 15.28% of the stock is owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.